Remove .Net Remove 2017 Remove Invest Remove Report
article thumbnail

Why 2017 Should be a Great Year to Raise Venture Capital

Both Sides of the Table

The conclusion of our report was that winter did come, but it was mild and short. We are now publishing some of the VC survey data the report used and the results are clear — it’s a great time to be a startup raising venture capital.

article thumbnail

How To Get Your Startup Funded - Tips From Entrepreneur and Renowed Angel Investor Jason Calacanis

SoCal Tech Calendar

Tuesday, September 26, 2017 -- How To Get Your Startup Funded - Tips From Entrepreneur and Renowed Angel Investor Jason Calacanis. Jason Calacanis founded Silicon Alley Reporter, Weblogs Inc, Mahalo, and Inside.com. He turned down a $20 million offer for Silicon Alley Reporter.

Tips 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Xconomy Special Report: 12 San Diego Tech Startup to Watch in 2017

Xconomy

million in a Series D round of investment capital, according to founder and chairman Tony Farwell. I widened my net this year. The startups selected for this year’s list began, as it did last year, with a master list of companies screened by the San Diego Venture Group for its annual venture summit.

article thumbnail

10 Negatives That Still Make Going Public A High Risk

Startup Professionals Musings

According to a recent Ernst & Young global report , the first half of 2017 was the most active first half by global number of IPOs since 2007. Thus, there is tremendous pressure to increase current earnings, and little appetite for strategic investments. Startups going public are laid open to competitors and critics.

Startup 87
article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

. —Cambridge-based startup Amylyx Pharmaceuticals raised a $5 million Series A round from Morningside Venture, the ALS Investment Fund, and former Genzyme CEO Henri Termeer to develop a drug meant to stop the death of nerve cells in patients with amyotrophic lateral sclerosis. Alex Lash contributed to this report.

Pricing 40